NEW YORK, Oct 2 (Reuters) - Amicus Therapeutics Inc (FOLD.O) shares plunged 33.4 percent to $5.66 in extended trade on Friday after the company said its Plicera treatment for Gaucher disease failed to meet its endpoint in a Phase 2 study and does not expect the treatment to advance into phase 3 development. [ID:nWNAB5752]
(Reporting by Chuck Mikolajczak)
WASHINGTON (Reuters) - With 60 votes in hand, Senate Democrats cruised on Sunday toward an expected victory on the first of three crucial test votes that will put a broad healthcare overhaul on the path to passage by Christmas. | Video
On the last day of every month, shoppers at Walmart load their carts with food and household items and wait for the midnight hour. Is this the new normal in America? Full Article
The battered M&A sector will make a tepid recovery in the coming year and three hot sectors will lead the way, according to a Thomson Reuters analysis. Full Article
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
